Applicant: ZHI et al. Serial No.: 10/590,119 Filed : August 18, 2006

Supplemental Preliminary Amendment

AMENDMENTS TO THE CLAIMS:

Claims 1-78 and 82 are pending. Please amend claims 1-3, 8, 12, 21, 24, 26-30, 34 - 46, 51, 52, 59 - 61, 71, 73, 76, 78, and 82 as indicated below. This listing of claims replaces all prior versions, and listings of claims, in the application.

LISTING OF CLAIMS:

1. (Currently amended) A compound of having a structure selected from among Formula I, Formula II, Formula IV, Formula V, [[and]] or Formula VI:

$$R^{3a}$$
 R^{6}
 R^{7}
 R^{8}
 R^{10}
 R^{10}
 R^{5}
 R^{10}
 R^{10}
 R^{10}

$$R^{3}$$
 R^{6a}
 R^{7a}
 R^{12}
 R^{13}
 $R^$

$$R^{15}$$
 R^{16}
 R^{6}
 R^{7}
 R^{8}
 R^{10}
 R^{14}
 R^{17}
 R^{10}
 R^{11}
(III)

$$R^{16}$$
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{17}
 R^{12}
 R^{13}
 R^{13}
 R^{15}
 R^{15}
 R^{16}
 R^{17}
 R^{19}
 R^{10}
 R^{19}
 R^{10}
 R^{10}

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

$$R^{19}$$
 R^{19}
 R^{19}
 R^{20}
 R^{22}
 R^{23}
 R^{24}
 R^{24}
 R^{21}
 R^{26}
 R^{25}
 R^{25}
 R^{25}

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{25}
 R^{25}
 R^{25}

wherein:

 R^1 and R^2 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^3 , R^{3a} , R^4 , and R^5 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein provided that if R^1 is NO_2 and R^{3a} is F, then at least one of R^2 and R^4 and R^5 is not hydrogen; and wherein provided that if R^1 is NO_2 and R^3 is F, then Z is not O;

 R^6 , R^7 , R^{10} , and R^{11} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^{6a} and R^{7a} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl; or R^{6a} and R^{7a} together form a carbonyl;

 R^8 and R^9 [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally

Applicant: ZHI et al.
Serial No.: 10/590,119
Filed: August 18, 2006

substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$;

 R^{12} and R^{13} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , NR^AR^B , SR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, an optionally substituted C_2 - C_6 alkenyl, and $(CH_2)_mR^C$;

R¹⁴ and R¹⁵ [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^{18} and R^{19} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, $NHCOR^A$, $NHCONR^AR^B$, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$;

 R^{20} and R^{21} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl; wherein if R^{18} is NO_2 and X is O, then at least one of R^{19} , R^{20} , and R^{21} is not hydrogen, and wherein if R^{19} is NO_2 and X is C, then at least one of R^{18} , R^{20} , and R^{21} is not hydrogen;

 R^{22} is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^6 , CO_2R^A , $CONR^AR^B$, SO_2R^A , an optionally substituted aryl, an optionally substituted heteroaryl, $CH_2CH(R^D)OR^A$, $CH_2CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$, wherein the optionally substituted aryl or optionally substituted heteroaryl is optionally substituted with a substituent selected from among F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

 R^{23} and R^{24} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 alkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8

Applicant : ZHI *et al.*Serial No. : 10/590,119
Filed : August 18, 2006

heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$; or R^{23} and R^{24} together form a carbonyl group, provided that if R^{18} is NO_2 and X is NH, then R^{23} and R^{24} do not together form a carbonyl group;

R²² and R²³ are optionally linked to form a ring;

 R^{23} and R^{25} are optionally linked to form a ring;

X is selected from among O, S, CR^AR^B , NR^D , and a bond; wherein if X is CR^AR^B or a bond, then R^{25} and R^{26} [[are]] each independently <u>is</u> selected from among a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

and wherein if X is selected from among O, S, or NR^D , then R^{25} and R^{26} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

 R^A and R^B [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from among an optionally substituted aryl and an optionally substituted heteroaryl that is optionally <u>substituted</u> with a substituent selected from among F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} haloalkyl, and an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from among O, S, CRARB, and NRD;

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

n is 0, 1, or 2; and

m is 1 or 2;

or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.

2. (Currently amended) The compound of claim 1 of having Formula II or Formula IV:

wherein wherein:

 R^1 and R^2 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

R³, R⁴, and R⁵ [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A, an optionally substituted C₁-C₄ alkyl, and an optionally substituted C₁-C₄ haloalkyl; wherein provided that if R¹ is NO₂ and R³ is F, then Z is not O;

 R^6 , R^7 , and R^{10} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^{6a} and R^{7a} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl; or R^{6a} and R^{7a} together form a carbonyl;

 R^9 is selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, C_1 - C_2 - C_3 - C_4 - C_5 - C_6

 R^{12} and R^{13} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , NR^AR^B , SR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, an optionally substituted C_2 - C_6 alkenyl, and $(CH_2)_mR^C$;

 R^{14} and R^{15} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^A and R^B [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from among an optionally substituted aryl and an optionally substituted heteroaryl that is optionally <u>substituted</u> with a substituent selected from among F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from among O, S, CRARB, and NRD;

n is 0, 1, or 2; and

m is 1 or 2.

- 3. (Currently amended) The compound of claim 1, wherein R^1 is selected from NO_2 [[and]] or CN.
 - 4. (Previously presented) The compound of claim 1, wherein R¹ is NO₂.

Applicant: ZHI et al.

Serial No.: 10/590,119

Attorney's Docket No.: 18202-028US1 / 1112US

Supplemental Preliminary Amendment

Serial No.: 10/590,119 Filed: August 18, 2006

5. (Previously presented) The compound of claim 1, wherein R¹ is CN.

6. (Previously presented) The compound of claim 1, wherein R^2 is an optionally substituted C_1 - C_4 alkyl or an optionally substituted C_1 - C_4 haloalkyl.

- 7. (Previously presented) The compound of claim 1, wherein R^2 is C_1 - C_4 alkyl or trifluoromethyl.
- 8. (Currently amended) The compound of claim 1, wherein R^3 , R^4 , and R^5 [[are]] each independently is selected from among hydrogen, F, Cl, and an optionally substituted C_1 - C_4 alkyl.
 - 9. (Previously presented) The compound of claim 1, wherein R³ is hydrogen.
 - 10. (Previously presented) The compound of claim 1, wherein R⁴ is hydrogen.
 - 11. (Previously presented) The compound of claim 1, wherein R⁵ is hydrogen.
- 12. (Currently amended) The compound of claim 1, wherein R^{6a} and R^{7a} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, and an optionally substituted C_1 - C_6 heterohaloalkyl or R^{6a} and R^{7a} together form a carbonyl.
 - 13. (Previously presented) The compound of claim 1, wherein R^{6a} is hydrogen.
- 14. (Previously presented) The compound of claim 1, wherein R^{7a} is hydrogen or an optionally substituted C_1 - C_6 alkyl.
- 15. (Previously presented) The compound of claim 1, wherein R^{7a} is hydrogen or methyl.
 - 16. (Previously presented) The compound of claim 1, wherein R^{7a} is hydrogen.
 - 17. (Previously presented) The compound of claim 1, wherein R^{7a} is methyl.
- 18. (Previously presented) The compound of claim 1, wherein R^{6a} and R^{7a} together form a carbonyl.
- 19. (Previously presented) The compound of claim 1, wherein R^{10} is selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl and $(CH_2)_m R^C$.
 - 20. (Previously presented) The compound of claim 1, wherein R¹⁰ is hydrogen.
- 21. (Currently amended) The compound of claim 1, wherein R^9 is selected from among hydrogen, F, Cl, Br, I, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, COR^A , CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$.
- 22. (Previously presented) The compound of claim 1, wherein R^9 is hydrogen, formyl, hydroxy C_1 - C_6 alkyl, hydroxyhalo C_1 - C_6 alkyl, C_1 - C_6 alkyl, C_1 - C_6 alkyl, amino C_1 - C_6 alkyl, carboxy, or C_1 - C_6 alkylcarbonyloxy C_1 - C_6 alkyl.

Attorney's Docket No.: 18202-028US1 / 1112US

Applicant: ZHI et al. Serial No.: 10/590,119 **Supplemental Preliminary Amendment** Filed : August 18, 2006

23. (Previously presented) The compound of claim 1, wherein R⁹ is hydrogen, formyl, hydroxymethyl, 1-hydroxy-2,2,2-trifluoromethyl, tributylsilyloxymethyl, ethoxycarbonyl, aminomethyl, carboxy, or acetyoxymethyl.

- 24. (Currently amended) The compound of claim 1, wherein R¹² and R¹³ [[are]] each independently is selected from among hydrogen, F, Cl, ORA, an optionally substituted C₁-C₆ alkyl, an optionally substituted C₁-C₆ heterohaloalkyl and (CH₂)_mR^C.
- 25. (Previously presented) The compound of claim 1, wherein R¹³ is hydrogen, F, OH or benzyl.
- 26. (Currently amended) The compound of claim 1, wherein the compound has of formula IIA:

$$R^{2}$$
 R^{3}
 R^{12}
 R^{12}
 R^{13}
 R^{14}
 R^{10}
 R^{15}

27. (Currently amended) The compound of claim 1, wherein the compound has of formula IIB:

$$R^{1}$$
 R^{1}
 R^{1}
 R^{1}
 R^{1}
 R^{1}
 R^{1}
 R^{1}

28. (Currently amended) The compound of claim 1, wherein R¹ is selected from among NO₂ [[and]] or CN;

R² is hydrogen, optionally substituted C₁-C₄ alkyl or an optionally substituted C₁-C₄ haloalkyl;

R³, R⁴, and R⁵ [[are]] each independently is selected from among hydrogen, F, Cl, and an optionally substituted C₁-C₄ alkyl;

R^{6a} and R^{7a} [[are]] each independently is selected from among hydrogen and an optionally substituted C_1 - C_6 alkyl; an optionally substituted C_1 - C_6 heterohaloalkyl, or R^{6a} and Applicant: ZHI et al.

Serial No.: 10/590,119

Attorney's Docket No.: 18202-028US1 / 1112US

Supplemental Preliminary Amendment

Serial No.: 10/590,119 Filed: August 18, 2006

R^{7a} together form a carbonyl;

 R^9 is selected from among hydrogen, F, Cl, Br, I, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, COR^A , CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$;

R¹⁰ is hydrogen; and

 R^{12} and R^{13} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl and $(CH_2)_mR^C$.

29. (Currently amended) The compound of claim 1, wherein R¹ is selected from among NO₂ [[and]] or CN;

R² is hydrogen or trifluoromethyl;

R³, R⁴, [[are]] and R⁵ each is hydrogen;

R^{7a} is hydrogen or methyl and R^{6a} is hydrogen; or R^{6a} and R^{7a} together form a carbonyl;

R⁹ is selected from among hydrogen, formyl, hydroxymethyl, 1-hydroxy-2,2,2-trifluoromethyl, tributylsilyloxymethyl, ethoxycarbonyl, aminomethyl, carboxy, and acetyoxymethyl acetyloxymethyl;

R¹⁰ is hydrogen;

R¹² is hydrogen; and

R¹³ is selected from among hydrogen, F, OH and benzyl.

30. (Currently amended) The compound of claim 1, wherein the compound has formula is selected from among:

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

$$R^{2}$$
 R^{3}
 R^{13}
 R^{14}
 R^{15}
 R^{15}

- 31. (Original) The compound of claim 30, wherein R^{7a} is an optionally substituted C_1 - C_6 heterohaloalkyl.
- 32. (Original) The compound of claim 30, wherein R^9 is an optionally substituted C_1 - C_6 heterohaloalkyl.
- 33. (Original) The compound of claim 30, wherein R^{13} is an optionally substituted C_1 - C_6 heterohaloalkyl.
- 34. (Currently amended) The compound of claim 30, wherein the compound has formula is:

$$R^{2}$$
 R^{3}
 R^{13}
 R^{13}

35. (Currently amended) The compound of claim 30, wherein the compound has formula is:

Attorney's Docket No.: 18202-028US1 / 1112US

Applicant: ZHI et al. Serial No.: 10/590,119 **Supplemental Preliminary Amendment** Filed : August 18, 2006

$$R^2$$
 O_2N
 R^9
 NC
 R^8
 R^8
 R^7a
 R^{7a}
 R^{7a}
 R^{13}
 R^2
 R^9
 NC
 R^9

36. (Currently amended) The compound of claim 1, wherein the compound has of Formula IIC or Formula IID:

$$R^{6a}$$
 R^{7a}
 R^{12}
 R^{6a}
 R^{7a}
 R^{12}
 R^{6a}
 R^{7a}
 R^{12}
 R^{13}
 R^{6a}
 R^{7a}
 R^{12}
 R^{13}
 R^{13}
 R^{12}
 R^{13}
 R^{13}
 R^{12}
 R^{13}
 R^{13}
 R^{14}
 R^{15}
 R^{15}

37. (Currently amended) The compound of claim 36, wherein R¹ is NO₂;

R₂ is hydrogen or haloalkyl;

R³, R⁴, R⁵, R^{6a}, R^{7a}, R⁹, R¹², and R¹³ [[are]] each is hydrogen; and

R⁹ is selected from among CO₂R^A, CH(R^D)OR^A, and CH(R^D)NR^AR^B.

38. (Currently amended) The compound of claim 36, wherein R¹ is NO₂;

R₂ is hydrogen or trifluoromethyl;

 R^3 , R^4 , R^5 , R^{6a} , R^{7a} , R^9 , R^{12} , and R^{13} [[are]] each is hydrogen; and

R⁹ is selected from among hydroxymethyl, ethoxycarbonyl and acetyoxymethyl.

39. (Currently amended) The compound of claim 1, wherein the compound has formula is:

Supplemental Preliminary Amendment

Applicant : ZHI *et al.*Serial No. : 10/590,119
Filed : August 18, 2006

$$R^{16}$$
 R^{16}
 R^{16}
 R^{16}
 R^{10}
 R^{12}
 R^{13}
 R^{13}
 R^{14}
 R^{17}

40. (Currently amended) The compound of claim 1, wherein the compound has formula is:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{10}
 R^{12}
 R^{13}
 R^{14}
 R^{17}

41. (Currently amended) The compound of claim 1, wherein the compound has formula is:

42. (Currently amended) The compound of claim 1, wherein the compound has of Formula V or Formula VI:

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

wherein R¹⁸ and R¹⁹ [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{20} and R^{21} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl; wherein if R^{18} is NO_2 and X is O, then at least one of R^{19} , R^{20} , and R^{21} is not hydrogen, and wherein if R^{19} is NO_2 and X is C, then at least one of R^{18} , R^{20} , and R^{21} is not hydrogen;

 R^{22} is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl, an optionally substituted C_1 - C_4 heteroalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, COR^6 , CO_2R^A , $CONR^AR^B$, SO_2R^A , an optionally substituted aryl, an optionally substituted heteroaryl, $CH_2CH(R^D)OR^A$, $CH_2CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$, wherein the optionally substituted aryl or optionally substituted heteroaryl is optionally substituted with a substituent selected from among F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{23} and R^{24} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$; or R^{23} and R^{24} together form a carbonyl group, provided that if R^{18} is NO_2 and X is NH, then R^{23} and R^{24} do not together form a carbonyl group; or

Applicant: ZHI et al.
Serial No.: 10/590,119
Filed: August 18, 2006

R²² and R²³ are optionally linked to form a ring; or

R²³ and R²⁵ are optionally linked to form a ring;

 R^{25} is selected from among a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$;

X is selected from among O, S, CRARB, NRD, and a bond;

wherein if X is CR^AR^B or a bond, then R^{25} and R^{26} [[are]] each independently <u>is</u> selected from among a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

and wherein if X is O, S, or NR^D, then R²⁵ and R²⁶ [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_m R^C$; or R^{25} and R^{26} together form a carbonyl group;

 R^A and R^B [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

Applicant: ZHI et al.
Serial No.: 10/590,119
Filed: August 18, 2006

 R^{C} is selected from among an optionally substituted aryl and an optionally substituted heteroaryl that is optionally <u>substituted</u> with a substituent selected from among F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from among O, S, CRARB, and NRD;

n is 0, 1, or 2; and

m is 1 or 2.

43. (Currently amended) The compound of claim 1, wherein the compound has of Formula [[VI]] V, wherein n is 1:

$$R^{19}$$
 R^{19}
 R^{19}
 R^{20}
 R^{22}
 R^{23}
 R^{24}
 R^{24}

44. (Currently amended) The compound of claim 1 of Formula V, wherein X is CR^AR^B, and R^A and R^B each is hydrogen: the compound has Formula:

$$R^{19}$$
 R^{19}
 R^{20}
 R^{22}
 R^{23}
 R^{24}
 R^{21}
 R^{26}
 R^{25}

45. (Currently amended) The compound of claim 1 of Formula V, wherein X is O: the compound has Formula V:

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

46. (Currently amended) The compound of claim 1, wherein R¹⁸ and R¹⁹ [[are]] each independently <u>is</u> selected from among hydrogen, NO₂, and an optionally substituted C₁-C₄ alkyl;

 R^{22} is hydrogen, an optionally substituted C_1 - C_4 alkyl and an optionally substituted C_1 - C_4 haloalkyl;

 $R^{23}\, and\, R^{24}\, \hbox{[[are]]}$ each independently \underline{is} hydrogen or an optionally substituted $C_1\text{-}C_4$ alkyl; and

R²⁵ and R²⁶ [[are]] each <u>is</u> hydrogen.

- 47. (Previously presented) The compound of claim 1, wherein R¹⁸ is NO₂.
- 48. (Previously presented) The compound of claim 1, wherein R¹⁹ is NO₂.
- 49. (Previously presented) The compound of claim 1, wherein R²² is hydrogen, heterohaloalkyl or haloalkyl.
- 50. (Previously presented) The compound of claim 1, wherein R²² is hydrogen or trifluoroethyl.
- 51. (Currently amended) The compound of claim 1, wherein R^{23} and R^{24} [[are]] each independently is hydrogen or methyl.
- 52. (Currently amended) The compound of claim 1, wherein the compound has Formula VI:

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{25}

- 53. (Original) The compound of claim 52, wherein R¹⁸ is NO₂.
- 54. (Original) The compound of claim 53, wherein R^{19} is NO_2 .
- 55. (Original) The compound of claim 52, wherein R^{22} is hydrogen, haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl or an optionally substituted C_1 - C_4 heterohaloalkyl.
- 56. (Previously presented) The compound of claim 52, wherein R²² is hydrogen or trifluoroethyl.
- 57. (Original) The compound of claim 52, wherein R^{23} is hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted C_1 - C_4 alkyl.
- 58. (Previously presented) The compound of claim 1, wherein R²⁵ is hydrogen, methyl or methoxyphenyl.

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

59. (Currently amended) The compound of claim 1, wherein the compound has of Formula III:

$$R^{15}$$
 R^{16}
 R^{6}
 R^{7}
 R^{8}
 R^{10}
 R^{14}
 R^{17}
 R^{10}
 R^{11}

where wherein:

 R^1 and R^2 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^{3a} , R^4 , and R^5 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein provided that if R^1 is NO_2 and R^{3a} is F, then at least one of R^2 and R^4 and R^5 is not hydrogen;

 R^6 , R^7 , R^{10} , and R^{11} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^8 and R^9 [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, C_1 - C_2 - C_3 - C_4 - C_5 - C_6 - $C_$

 R^{14} and R^{15} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A,

Applicant: ZHI et al.
Serial No.: 10/590,119
Filed: August 18, 2006

CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^A and R^B [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from among an optionally substituted aryl and an optionally substituted a heteroaryl that is optionally substituted with a substituent selected from among F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} haloalkyl, and an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl; and m is 1 or 2;

wherein the compound is selected with a proviso provided that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is other than hydrogen, alkyl, haloalkyl, alkenyl, and alkynyl.

- 60. (Currently amended) The compound of claim 59, wherein the compound is selected with a proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is heterohaloalkyl.
- 61. (Currently amended) The compound of claim 1, wherein the compound has of Formula I:

wherein wherein:

 R^1 and R^2 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

Applicant: ZHI et al. Attorney's Docket No.: 18202-028US1 / 1112US
Serial No.: 10/590.119
Supplemental Preliminary Amendment

Serial No.: 10/590,119 Filed: August 18, 2006

 R^{3a} , R^4 , and R^5 [[are]] each independently <u>is</u> selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein provided that if R¹ is NO₂ and R^{3a} is F, then at least one of R² and R⁴ and R⁵ is not hydrogen;

 R^6 , R^7 , R^{10} , and R^{11} [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^8 and R^9 [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, C_1 - C_2 - C_3 - C_4 - C_6 - $C_$

 R^A and R^B [[are]] each independently <u>is</u> selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from among an optionally substituted aryl and an optionally substituted a heteroaryl that is optionally substituted with a substituent selected from among F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl; and m is 1 or 2[[,]];

the compound is selected with a proviso provided that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is heterohaloalkyl.

62. (Previously presented) A compound of claim 1, wherein the compound is selected from among:

N,N-bis(2,2,2-trifluoroethyl)-3-methyl-4-nitroaniline (compound 101);

N,N-bis(2,2,2-trifluoroethyl)-4-nitroaniline (compound 102);

Applicant : ZHI *et al*.

Serial No. : 10/590,119

Filed : August 18, 2006

- 4-(Bis(2,2,2-trifluoroethyl)amino)-2-(trifluoromethyl)benzonitrile (compound 103); (5R)-N-(4-nitrophenyl)-5-(dimethyl-tert-butylsilyloxymethyl)-2-pyrrolidone (compound 104);
- (5R)-N-(4-nitrophenyl)-5-(hydroxymethyl)-2-pyrrolidone (compound 105);
- (2R)-N-(4-nitro-3-trifluoromethylphenyl)-2-(dimethyl-tert-butylsilyloxymethyl)pyrrolidine (compound 106);
- (2R)-N-(4-nitro-3-trifluoromethylphenyl)-2-(hydroxymethyl)pyrrolidine (compound 108);
- (2R)-N-(4-nitrophenyl)-2-(hydroxymethyl)pyrrolidine (compound 109);
- (2R)-N-(3-Trifluoromethyl-4-nitrophenyl)-2-formylpyrrolidine (compound 110);
- (2*R*)-*N*-(3-Trifluoromethyl-4-nitrophenyl)-2-(1-(*S*)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 111);
- (2*R*)-*N*-(3-Trifluoromethyl-4-nitrophenyl)-2-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 112);
- (2S)-N-(4-nitrophenyl)-2-(hydroxymethyl)pyrrolidine (compound 113);
- (2R)-N-(4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 114);
- (2R)-N-(4-nitrophenyl)-2-(R)-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 115);
- (2S)-N-(4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 116);
- (2S)-N-(4-nitrophenyl)-2-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 117);
- 3-(3-Methoxyphenyl)-6-nitro-2,7-dimethyl-1H-indole (compound 118);
- 4-[Bis-(2,2,2-trifluoroethyl)amino]-2-chloro-3-methyl-benzonitrile (compound 119);
- cis-2,5-Dimethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 120);
- trans-2,5-dimethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 121);
- 1-(4-Nitro-3-trifluoromethylphenyl)-piperidine-2-carboxylic acid ethyl ester (compound 122);
- 1-(4-Nitro-3-trifluoromethylphenyl)-4-(hydroxymethyl)-piperidine (compound 123);
- (1-(3-trifluoromethyl-4-nitrophenyl)piperidin-2-yl)methyl acetate (compound 124);
- 4-(2-Hydroxymethyl-pyrrolidin-1-yl)-benzonitrile (compound 125);
- 4-Benzyl-2-hydroxymethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 126);
- 2-Fluoro-4-(2-hydroxymethyl-pyrrolidin-1-yl)-benzonitrile (compound 127);
- 4-Hydroxy-1-(4-nitrophenyl)-pyrrolidine-2-carboxylic acid ethyl ester (compound 128);
- 4-Hydroxy-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine-2-carboxylic acid ethyl ester (compound 129);

Applicant: ZHI et al.

Serial No.: 10/590,119

Attorney's Docket No.: 18202-028US1 / 1112US

Supplemental Preliminary Amendment

Filed : August 18, 2006

5-Hydroxymethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidin-3-ol (compound 130);

- 2-(Aminomethyl)-1-(4-Nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 131);
- 4-Hydroxy-1-(4-nitrophenyl)-pyrrolidine-2-carboxylic acid (compound 132); and
- 4-Hydroxy-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine-2-carboxylic acid (compound 133);

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

- 63. (Previously presented) The compound of claim 1, wherein the compound is a selective androgen receptor modulator.
- 64. (Previously presented) The selective androgen receptor modulator of claim 63, wherein the compound is an androgen receptor agonist.
- 65. (Previously presented) The selective androgen receptor modulator of claim 63, wherein the compound is an androgen receptor antagonist.
- 66. (Previously presented) The selective androgen receptor modulator of claim 63, wherein the compound is an androgen receptor partial agonist.
- 67. (Previously presented) The selective androgen receptor modulator of claim 63, wherein the compound is a tissue-specific modulator.
- 68. (Previously presented) The compound of claim 1, wherein the compound is a selective androgen binding compound.
- 69. (Previously presented) A method for modulating an activity of an androgen receptor, comprising contacting an androgen receptor with a compound of claim 1.
 - 70. (Original) The method of claim 68, wherein the androgen receptor is in a cell.
- 71. (Currently amended) A method for identifying a compound that is capable of modulating modulates an activity of an androgen receptor comprising:

contacting a cell expressing an androgen receptor with a compound of claim 1; and monitoring an effect of the compound upon the cell.

- 72. (Previously presented) A method for treating a patient having a condition susceptible to treatment with an androgen receptor modulator, comprising administering to the patient a pharmaceutical agent comprising a compound of claim 1.
- 73. (Currently amended) The method of claim 72, wherein the condition is selected from among maintenance of muscle strength and function; reversal or prevention of frailty or age-related functional decline in the elderly; treatment of catabolic side effects of glucocorticoids; treatment of reduced bone mass, density or growth; treatment of chronic fatigue syndrome; chronic myalgia; treatment of acute fatigue syndrome and muscle loss;

Applicant : ZHI et al.

Serial No. : 10/590,119

Attorney's Docket No.: 18202-028US1 / 1112US

Supplemental Preliminary Amendment

Filed : August 18, 2006

accelerating of wound healing; accelerating bone fracture repair; accelerating healing of complicated fractures; in joint replacement; prevention of post-surgical adhesion formation; acceleration of tooth repair or growth; maintenance of sensory function; treatment of periodontal disease; treatment of wasting secondary to fractures and treatment of wasting in connection with chronic obstructive pulmonary disease, treatment of wasting in connection with chronic liver disease, treatment of wasting in connection with AIDS, cancer cachexia, burn and trauma recovery, chronic catabolic state, eating disorders and chemotherapy; treatment of cardiomyopathy; treatment of thrombocytopenia; treatment of growth retardation in connection with Crohn's disease; treatment of short bowel syndrome; treatment of irritable bowel syndrome; treatment of inflammatory bowel disease; treatment of Crohn's disease and ulcerative eolits colitis; treatment of complications associated with transplantation; treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness; treatment of obesity and growth retardation associated with obesity; treatment of anorexia; treatment of hypercortisolism and Cushing's syndrome; Paget's disease; treatment of osteoarthritis; induction of pulsatile growth hormone release; treatment of osteochondro-dysplasias; treatment of depression, nervousness, irritability and stress; treatment of reduced mental energy and low self-esteem; improvement of cognitive function; treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction; lowering blood pressure; protection against ventricular dysfunction or prevention of reperfusion events; treatment of adults in chronic dialysis; reversal or slowing of the catabolic state of aging; attenuation or reversal of protein catabolic responses following trauma; reducing cachexia and protein loss due to chronic illness; treatment of hyperinsulinemia; treatment of immunosuppressed patients; treatment of wasting in connection with multiple sclerosis or other neurodegenerative disorders; promotion of myelin repair; maintenance of skin thickness; treatment of metabolic homeostasis and renal homeostasis; stimulation of osteoblasts, bone remodeling and cartilage growth; regulation of food intake; treatment of insulin resistance; treatment of insulin resistance in the heart; treatment of hypothermia; treatment of congestive heart failure; treatment of lipodystrophy; treatment of muscular atrophy; treatment of musculoskeletal impairment; improvement of the overall pulmonary function; treatment of sleep disorders; and the treatment of the catabolic state of prolonged critical illness; treatment of hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, benign prostate hypertrophy, adenomas and neoplasies of the prostate and malignant tumor cells containing the androgen receptor; osteosarcoma; hypercalcemia of

Applicant: ZHI et al.

Serial No.: 10/590,119

Attorney's Docket No.: 18202-028US1 / 1112US

Supplemental Preliminary Amendment

Filed : August 18, 2006

malignancy; metastatic bone disease; treatment of spermatogenesis, endometriosis and polycystic ovary syndrome; counteracting preeclampsia, eclampsia of pregnancy and preterm labor; treatment of premenstrual syndrome; treatment of vaginal dryness; age related decreased testosterone levels in men, male menopause, hypogonadism, male hormone replacement, male and female sexual dysfunction, male and female contraception, hair loss, Reaven's Syndrome and the enhancement of bone and muscle strength.

74. (Previously presented) A method according to claim 72, wherein the patient has a condition selected from among acne, male-pattern baldness, wasting diseases, hirsutism, hypogonadism, osteoporoses, infertility, impotence and cancer.

- 75. (Previously presented) A method for stimulating hematopoiesis in a patient, comprising administering to the patient a pharmaceutical agent comprising a compound of claim 1.
- 76. (Currently amended) A method of contraception, comprising administering to a patient a pharmaceutical agent comprising a compound of claim 1.
- 77. (Previously presented) A method of improving athletic performance in an athlete, comprising administering to the athlete a pharmaceutical agent comprising a compound of claim 1.
- 78. (Currently amended) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutical pharmaceutically acceptable carrier.

Claims 79-81 (Cancelled).

82. (Currently amended) An article of manufacture, comprising: packaging material;

a compound [[of]] of claim 1 that is effective for modulating the activity of androgen receptor, or for treatment, prevention or amelioration of one or more symptoms of androgen receptor mediated diseases or disorders, or diseases or disorders in which androgen receptor activity is implicated, within the packaging material; and

a label that indicates that the compound or composition, or pharmaceutically acceptable derivative thereof, is used for modulating the activity of androgen receptor or for treatment, prevention or amelioration of one or more symptoms of androgen receptor mediated diseases or disorders, or diseases or disorders in which androgen receptor activity is implicated.